Human Longevity Inc is a genomics and cell therapy-based diagnostic and therapeutic company. The company is focused on developing cell-based therapeutics to address age-related decline in endogenous stem cell function, concentrating on cancer, diabetes and obesity, heart and liver diseases, and dementia. HLI uses machine learning and artificial intelligence to integrate data from an individual's whole genome, brain and body imaging via MRI, cardiac CT calcium scan, and metabolic tests.In April 2015, the company was granted CLIA (Clinical Laboratory Improvement Amendments of 1988) certification, by the state of California.In January 2016, Human Longevity agreed to purchase LifebankUSA and the acquisition was expected to complete in the first quarter of 2016.In November 2015, Human Longevity acquired Cypher Genomics.In April 2016, the company completed an offering of series B preferred stock, raising in excess of $220 million.In March 2014, the company was capitalized